Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    • News

  • Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    • News

  • EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    • News

  • RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    • News

  • BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    • News

  • AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    • News

  • Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    • News

  • Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    • News

  • FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    • News

  • Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    • News

Archer delivers biochip milestone with a system integrating robots and wettable electronics

  • In News
  • November 16, 2022
  • Alfred Chan
Archer delivers biochip milestone with a system integrating robots and wettable electronics

Australian semiconductor company Archer Materials (ASX: AXE) is one step closer to the commercialisation of their deep tech biochip that could soon be used to detect some of the world’s most deadly transmittable diseases thanks to a major tech milestone.

The milestone has been achieved in an early-stage prototype where Archer successfully implemented an integrated biochip platform with a robotic handler that can seamlessly handle a sample into the biochip fluidics and graphene sensor, which can then display the readings on a connected computer. This progress is critical to Archer’s biochip given the nature of its capacity which has the potential to detect deadly diseases without the risk of contamination or transmission in lab settings.

“This is a significant step in the development of Archer’s biochip that has the potential for commercial applications,” said Archer CEO, Dr Mohammad Choucair.

“Archer will focus on building advanced and sophisticated versions of this system which could be used in commercial or applied research settings.

“The system will allow the Archer team to accurately, reliably, reproducibly, and quickly obtain data related to the Company’s biochip devices, which is importantly, required to establish commercial partnerships with global companies organising around the high-growth biosensing and diagnostics market.”

The system hardware and software employed paves the way for future designs which embed single-chip multiplexing, a much sought-after solution in medical diagnostics.

Enabling Archer to develop such a biochip is their industry-leading research and development of graphene devices. With nanoscale electronic, chemical, and physical properties, graphene is widely regarded as the next generation of biosensing applications, for which Archer’s biochip represents a paradigm shift within the global biotech industry.

The Archer biochip integrates liquid-gated graphene field effect transistors (gFETs) that are compatible with liquids, even using the liquid as part of the transistor, in what the company describes as, a ‘lab-on-a-chip’ that would be able to detect multiple biological targets.

The platform developed by Archer operates an end-to-end process that has been custom built by the Company. Having achieved this milestone, Archer will be able to advance the platform now that this critical handling process has been automated with robotics to improve the quality of readings generated by the sensing devices.

By using graphene, the ultrasensitive nature of gFETs is expected to offer greater analytical and detection capabilities than traditional electronic sensors for biological samples used in medical diagnostics.

The development of Archer’s graphene biochips complements their development of quantum computing processors, stemming from their 100% owned IP related to the biochip technology.

The graphene biochip utilised in this prototype milestone currently has patent applications pending in Australia and the US. Archer is well positioned to advance the prototype towards commercialisation courtesy of a strong cash balance of more than $25 million on hand with no debt.

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024
*Owners of this website are shareholders in a company mentioned in this article and have been engaged by them to assist in investor communications
  •  
  •  
  •  
  •  
  • archer materials
  • asx: axe
  • biochip
  • gfets
  • lab on a chip
  • mohammad choicair
  • quantum computing
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.